Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

A randomized phase 2b trial of baricitinib, an oral Janus kinase (<scp>JAK</scp>) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis

PaperCitations, authors & open-access status

A randomized phase 2b trial of baricitinib, an oral Janus kinase (<scp>JAK</scp>) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 261 citations, 2016 year and hybrid oa status.

261
Citations
2016
Year
hybrid
OA Status

Related on ScholarIQ

Maitreyi Raman
Author
British Journal of Dermatology
Journal
Psoriasis: Treatment and Pathogenesis
Topic
Psoriasis: Treatment and Pathogenesis
Topic
Dermatology and Skin Diseases
Topic
Spondyloarthritis Studies and Treatments
Topic
470M+ articles · free account